Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
Amount Raised
$80 Million
Round Type
Series C
ZugBiotechnologyHealth CareTherapeuticsDescription
Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the close of its oversubscribed $80 million Series C financing bringing its total venture funding to over $160 million to date. Viking Global Investors and General Atlantic co-led the financing, with participation by Cormorant Asset Management. Current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners, and Venrock Healthcare Capital Partners also participated in the round.
Quick answer
Pharvaris raised $80 Million in a Series C round, dated November 18, 2020. Pharvaris is based in Zug, Zug, Switzerland.
- How much did Pharvaris raise?
- Pharvaris raised $80 Million in a Series C round on November 18, 2020.
- What does Pharvaris do?
- Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.
- Where is Pharvaris based and how big is it?
- Pharvaris is based in Zug, Zug, Switzerland. Fundz records about 126 employees.
- Who are the decision-makers at Pharvaris?
- Fundz holds 1 contact at Pharvaris. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Pharvaris that raised within 45 days of this round, from Fundz verified event records.
- Neurogene raised $69M on December 29, 2020.
- Alpha Cognition raised $1.5M (Seed) on December 28, 2020.
- Definium Therapeutics raised $78K (Seed) on December 22, 2020.
- OnKure Therapeutics, Inc. raised $47M on December 21, 2020.
- TuHURA Biosciences raised $2.7M (Seed) on December 17, 2020.
- CytoDyn raised $1M (Seed) on December 16, 2020.
Who to call at Pharvaris, and when
A new round usually means Pharvaris is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Pharvaris raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pharvaris, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pharvaris. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pharvaris raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Pharvaris raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.